Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

HELP Committee Dems Block Antiabortion Provisions In Health Reform Markup
The Senate Health, Education, Labor and Pensions Committee on Monday rejected several Republican abortion-related amendments to the committee" health overhaul bill but adopted a Democratic amendment allowing health care providers who oppose abortion to contract with health plans, CQ HealthBeat reports. The committee voted mostly along party lines to reject an amendment by Sen. Orrin Hatch (R-Utah) that would have prohibited abortion coverage in a health care exchange for participants who receive government-subsidized coverage. Democrats said that the language could have been used to restrict abortion coverage in private insurance plans. The amendment failed in an 11-12 vote, with Sen. Bob Casey (D-Pa.) crossing party lines to support it. The committee also voted 11-12 to reject an amendment by Sen. Tom Coburn (R-Okla.) that would have specified that federal health reform legislation could not override state laws on parental notification when minors seek abortion services. The committee adopted by voice vote an amendment submitted by Sen. Christopher Dodd (D-Conn.) on behalf of committee Chair Edward Kennedy (D-Mass.), who is battling brain cancer. The amendment states that health care providers could not be excluded from contracting with health plans taking part in a health insurance exchange on the basis that the provider performs abortions or refuses to perform abortions except in an emergency if "performing abortions is contrary to the religious or moral beliefs of the provider or entity." Sen. Mike Enzi (R-Wyo.) said that he is concerned the amendment might be unconstitutional because Congress cannot legislate on religious issues. Sen. Kay Hagan (D-N.C.) expressed concern that the phrase "except in emergency" was not more clearly defined. Dodd declined Enzi"s request to withdraw the amendment until it could be clarified. The committee rejected Coburn"s amendment that was a more sweeping version of "conscience" protections for health care providers with religious or moral objections (Norman [1], CQ HealthBeat, 7/13). Dodd said he expects the committee to complete its work on the bill Tuesday night (Norman [2], CQ HealthBeat, 7/13).According to NPR"s "Morning Edition," abortion is one of the most likely issues to "throw a wrench into the already fragile gears" of health reform legislation. Sen. Chuck Grassley (R-Iowa) said, "I take a view that there"s almost anything (that can be compromised) in public affairs except probably the issue of abortion." Nineteen House Democrats recently sent a letter to House Speaker Nancy Pelosi (D-Calif.), saying, "We cannot support any health care reform proposal unless it explicitly excludes abortion from the scope of any government-defined or subsidized health insurance plan." Democratic pollster Mark Mellman said any new restrictions on abortion coverage in government-subsidized health plans might be unpopular with the public. "Right now most health care plans cover abortion, cover contraception, cover women"s reproductive health," Mellman said. He added, "To some extent what they"re talking about on Capitol Hill is taking away coverage that people already have. Americans want health care reform. But they will oppose health care reform if it takes away the coverage they now have for things like abortion and contraception." Mellman recently conducted a poll for the National Women"s Law Center that found that 75% of respondents would prefer to have an independent commission of medical experts and citizens, rather than lawmakers, decide what should be covered (Rovner, "Morning Edition," NPR, 7/14).

JustAnswer And Glaucoma Research Foundation Help Individuals See The Light In Preventing Blindness
JustAnswer®, the website where people go when they need answers from Doctors, Lawyers, Mechanics or other Experts, today announced it is partnering with the Glaucoma Research Foundation (GRF), as part of Vision Research Month. The collaboration is to help the non-profit educate, identify and treat individuals with glaucoma. This disease, diagnosed in 2.4 million people per year worldwide, leads to blindness if untreated.
News of the day
Connecticut: Small Businesses Struggle With Soaring Premiums, Unintended Consequences Of Old Law
"Premiums for small employers have been rising by double-digit increases for a few years, and they don"t have the negotiating power of larger employers," the Hartford (Conn.) Courant reports. This year"s increases are even higher than usual, on top of an economic recession. Connecticut businesses are resorting to drastic measures to preserve employee"s coverage, or are forced to drop it all together.
Nutrition

FDA Appointed Arthritis Advisory Committee Recommends U.S. Food And Drug Administration Approval For KRYSTEXXA(TM) For Refractory Chronic Gout

Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a vote of 14 to 1 that KRYSTEXXA(TM) (pegloticase), a biologic PEGylated uricase enzyme, be granted marketing approval by the FDA for the treatment of refractory chronic gout. Refractory chronic gout or treatment failure gout (TFG) is gout in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with conventional urate-lowering therapy at the maximum medically appropriate dose or for whom conventional urate-lowering therapy is contraindicated. The current target Prescription Drug User Fee (PDUFA) action date for the FDA"s decision as to whether to grant marketing approval for KRYSTEXXA is August 1, 2009. "We are very pleased with the Advisory Committee"s recommendation, which supports our belief that KRYSTEXXA has a favorable risk to benefit profile in patients suffering from TFG," said Paul Hamelin, President of Savient Pharmaceuticals, Inc. "KRYSTEXXA has the potential to provide an important new treatment option for patients with TFG, who currently have no other available treatment options, and many of whom suffer from serious pain and disability." The Advisory Committee"s recommendation, although not binding, will be considered by the FDA in its review of the Biologics License Application that Savient has submitted for KRYSTEXXA. ABOUT SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient is currently developing one product: KRYSTEXXA(TM) (pegloticase) as a therapy for patients with treatment failure gout, to control hyperuricemia and to manage the signs and symptoms of gout. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. FORWARD LOOKING LANGUAGE All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the efficacy and safety of KRYSTEXXA(TM) (pegloticase), our BLA filing with the FDA, the Advisory Committee, approval of the BLA, preparation for commercialization of KRYSTEXXA, and the market for KRYSTEXXA, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may not approve our BLA for KRYSTEXXA, notwithstanding the recommendation of the Advisory Committee; any delay or failure by us in completing the development of KRYSTEXXA; varying interpretations of our clinical and CMC data by the FDA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements. Savient Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009